clinical trial · NCT07218146
A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE)
Zai Lab (Shanghai) Co., Ltd.·phase3·recruiting·n = 480
Small-cell Lung CancerZL-1310Investigator's Choice of Therapy
brief summary
The purpose of this study is to evaluate the efficacy and safety of ZL-1310 compared to Investigator's Choice Therapy in participants with relapsed Small Cell Lung Cancer.
started
Nov 30, 2025
primary completion
Jun 30, 2028
completion
Nov 30, 2028
last updated
May 14, 2026
official title
A Randomized, Open-Label, Phase 3 Study of ZL-1310, a DLL3 Antibody-Drug Conjugate (ADC), Compared to Investigator's Choice Therapy in Participants With Relapsed Small Cell Lung Cancer
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol